MedPath

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Registration Number
NCT00108290
Lead Sponsor
US Department of Veterans Affairs
Brief Summary

In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a combination of chemotherapy and hormone therapy is being given for 6 months followed by surgery to remove the prostate.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  • High risk prostate cancer without evidence of bone metastasis.
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

VA Maryland Health Care System

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath